Expert Insights: Navigating the Evolving Treatment Landscape in NDMM

Opinion
Video

Panelists discuss how recent therapeutic advances, including novel drug combinations and personalized treatment approaches, are reshaping the standard of care for patients with newly diagnosed multiple myeloma (NDMM) while emphasizing the importance of risk stratification and early intervention strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      1 expert is featured in this series.
      Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
      3 experts are featured in this series.
      Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
      3 experts are featured in this series.
      Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
      Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
      Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
      The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
      The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
      Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC
      Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC
      1L Treatment for Advanced NSCLC
      1L Treatment for Advanced NSCLC
      3 experts are featured in this series.
      Recap: ELCC 2025 Highlights
      3 experts are featured in this series.
      Presented at ELCC 2025: Key Takeaways From KRYSTAL-7
      3 experts are featured in this series.
      ELCC 2025: Insights From the MARIPOSA Study
      Related Content
      Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

      Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

      Jason M. Broderick
      April 17th 2025
      Article

      Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its approval of the treatment last year.

      Read More

      Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

      Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

      Binod Dhakal, MD, MS;Jordyn Sava
      June 14th 2024
      Podcast

      In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

      Listen

      Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

      Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

      Tony Berberabe, MPH
      April 11th 2025
      Article

      A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

      Read More

      Advancing Myeloma Treatment With Blood-Based MRD Testing

      Advancing Myeloma Treatment With Blood-Based MRD Testing

      Jordyn Sava;Ben Derman, MD
      February 15th 2024
      Podcast

      In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

      Listen

      Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

      Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

      Jordyn Sava
      April 10th 2025
      Article

      Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

      Read More

      Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

      Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

      Targeted Oncology Staff
      April 8th 2025
      Article

      During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

      Read More